
Intellia Therapeutics (NTLA) Stock Forecast & Price Target
Intellia Therapeutics (NTLA) Analyst Ratings
Bulls say
Intellia Therapeutics is supported by a de-risked HAE franchise, as lonvo-z’s Phase 3 HAELO data showed an 87% reduction in mean monthly attacks versus placebo, with 62% of patients attack-free over the six-month period and no advisory committee meeting planned. FDA acceptance of the BLA with Priority Review and a March 10, 2027 PDUFA date meaningfully clarifies the path to what could become the first approved in vivo CRISPR therapy, while also establishing a major regulatory precedent for the platform. Financially, the company’s new $400M OrbiMed facility, including a potential additional $75M draw after approval, reduces near-term dilution risk and aligns liquidity with launch execution and future revenue milestones.
Bears say
Intellia Therapeutics is burdened by a still-immature CRISPR/Cas9 platform, with no approved genome-editing product and limited clinical trial experience, leaving the company exposed to outsized disappointment if development or efficacy data weaken. Its dependence on uncertain third-party intellectual property and partnerships with Novartis and Regeneron adds strategic risk, while any clinical setback could damage confidence in both the pipeline and the broader technology. Although lonvo-z has FDA Priority Review with a March 10, 2027 PDUFA date and forecast revenue of $8.8MM in 2027, $33.8MM in 2028, and $82.4MM in 2029, the need for additional equity financing implies dilution risk and commercialization remains limited by breakthrough attacks in 38% of patients.
This aggregate rating is based on analysts' research of Intellia Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction
Start investing in Intellia Therapeutics (NTLA)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Intellia Therapeutics (NTLA) Forecast
Intellia Therapeutics (NTLA) Analyst Forecast & Price Prediction
Start investing in Intellia Therapeutics (NTLA)
Order type
Buy in
Order amount
Est. shares
0 shares